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ABSTRACT 
Lifestyle and diet-related disorder type 2 diabetes (T2D), has reached epidemic margin globally. The relationships between diabetes 
and cancer are complex. However, evidence supports the hypothesis that obesity raises the risks of both T2D and certain cancers. A 
further complication arises from the controversy that drugs used in the treatment of T2D increase or decrease cancer risk or influence 
cancer diagnosis. Herein, we hypothesized that the antidiabetic medications can improve cancer outcome. In this study, we have 
studied the potency and efficacy of two well-known antidiabetic drugs metformin and sitagliptin. Although there are controversies 
for the usage of DDP4 inhibitors, we found that sitagliptin has a potent cytotoxic effect on both types of cancer cells (MCF7 and 
HepG2). It has also shown certain impact on early apoptogenic efficacy in HepG2 and late apoptogenic efficacy on MCF7 as well as 
the caspase-3 activity expression in both cell lines. In line of our study, it might be concluded that sitagliptin has significant 
antiproliferative and apoptogenic efficacy in MCF7 and HepG2 cancer cells, though it was observed to be lesser than that of 
metformin. Further thorough investigation in a cancer-diabetes animal model, as well as the trial on cancer-diabetic human subjects, 
is required to establish the efficacy of type 2 antidiabetic drugs in treating diabetic cancer patients. 
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Drug designing and development are being attempted all 
over the world to meet every day’s newer health 
complications, especially due to modern life style related 
diseases. Diabetes and cancer are the most dreaded 
diseases related to life styles of modern age. Apart from 
the cons of modern sedentary life style, we now a days, 
encounter a few more problems which lead to the serious 
outcomes due to several chronic and systemic diseases 
like – hormonal dysregulation, hyperglycaemia, 
metabolic syndrome and over all cancer. The present 
study relates the causes and their consequences with the 
contemporary interventions made by the scientific 
community. Most of the reasons, responsible for 
mentioned problems in human life style, are created by 
humans themselves. Behind the stated human diseases, 
excess use of chemicals and hormones do have a 
noteworthy presence. The result of this is accumulation 
of xenobiotic compounds in the human gut, liver and 
other tissues. This results in certain hormonal 
dysregulations in the body leading to various systemic 
diseases which in turn lead to certain mutations, sharing 
commonly contributory efficacy to result in 
carcinogenesis as well as diabetes. Apart from the 
ingestion of xenobiotic compounds and various other 
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cancer-causing agents in any or the other form, the 
mutation can take place due to the high quantity of ultra 
violet rays in the environment. 
Now, coming to the context of the present topic, we 
must say that using medications for what so ever reasons 
in an unsolicited manner is also largely responsible for 
various systemic disorders including the two diseases we 
are concerned about in this study. The unidentified side 
effects give reasons towards formation of various 
systemic and hormonal disorders. These disorders in 
turn give rise to diabetes and cancer. 
Our focus would be to illustrate the reported links 
between the two of the most dreaded diseases in the light 
of previous studies on treating cancer by type-2 anti-
diabetic drugs by other investigators and ours as well 
1, 2
. 
We shall look into the interventions made against cancer 
by some well documented anti-diabetic medicines. There 
are controversies of anticancer activity of certain anti-
diabetic drugs used in Type-2 diabetic patient having 
cancer and some are beneficial
2
. The multifunctional 
role of these drugs is mainly due to their involvement in 
different molecular signaling pathways. 
As stated earlier, that from previous reports from the 
scientific world, it was understood that diabetes and 
cancer are the most dreaded real-world health problems 
in the present decade. In course of developing newer 
drugs to combat cancer, several established drugs have 
been trialled against cancer. This took place in 
connection with the common symptoms shared by 
different life style related diseases. Often two diseases 
are resulted by a common dysregulation of cell 
signalling pathways. It is obvious then, that any 
substance that re-stabilizes the regulation of the 
aforesaid cellular signalling pathways, can definitely act 
against both the concerned diseases. On similar 
thoughts, investigators have been searching anti-cancer 
potentials in type-2 anti-diabetic drugs since the two 
diseases do share a set of certain common cellular states. 
Despite investigation into mechanisms linking Type-2 
diabetes and cancer, there is a gap in knowledge about 
pharmacotherapy in cancer patients. Epidemiologic 
studies have shown that diabetic cancer patients on 
different anti-diabetic treatments have different survival. 
The clinically relevant question is, whether certain anti-
diabetic agents promote cancer while others inhibit 
cancer progression
1, 2, 
3. Although insulin and glucose 
promoted cancer cell proliferation and contributed to 
chemoresistance, metformin and rosiglitazone 
suppressed cancer cell growth and induced apoptosis
3,4
. 
Pioglitazone have been shown to induce apoptosis, as 
well as adipocyte differentiation
2, 5
. Dipeptidyl 
dipeptidase-4 (DPP-4) inhibitor, a newly developed 
another group of drug used in diabetes 
6
. DPP-4 is a 
multifunctional cell surface protein that is widely 
expressed in most cell types including T lymphocytes 
7
. 
There is no expression of DPP-4 in normal healthy 
thyroid, while it is highly expressed in papillary thyroid 
carcinoma 
8
. The use of DPP-4 inhibitor together with 
glucagon like peptide-2 (GLP-2) led to increased 
proliferation as well as elevated migratory activity. 
Therefore, the DPP-4 inhibitor could increase the risk of 
promoting an already existing intestinal tumor and may 
support the potential of colon cancer cell to metastasize. 
Again DPP-4 inhibits malignant phenotype of prostate 
cancer cells by blocking bFGF signaling pathway 
9
. 
In the present investigation, we will be providing 
information about the efficacy of two groups of Type-2 
anti-diabetic drugs (Metformin & Sitagliptin) in breast 
and liver cancer cells. In the present investigation we 
will compare the anticancer activity of these drugs at the 
level of different molecular signalling pathways. 
MATERIALS AND METHODS 
Cell line procurement and Culture 
The cancer cell lines, MCF7 (Breast Cancer Cells) and 
HepG2 (Hepatocellular Carcinoma Cells) cells were 
kindly provided by Prof. Sanjay Ghosh, University of 
Calcutta. MCF-7 and HepG2 cells were maintained at 
37˚C in a 5% CO2 atmosphere in IMDM (GIBCO, Life 
Technologies, NY, USA) and DMEM (GIBCO, Life 
Technologies, NY, USA) respectively, with 10% FBS 
(GIBCO, Life Technologies, NY, USA), substituted 
with 50 units/ml penicillin and 50 mg/ml streptomycin 
(GIBCO, Life Technologies, NY, USA). 
Chemicals and Reagents 
Both of the drugs, sitagliptin and metformin, were 
purchased from SIGMA-ALDRICH (St. Louis, MO, 
USA). IMDM and DMEM culture media were 
purchased from GIBCO (Life Technologies, NY, USA), 
CellTiter-Blue
®
 for alamar blue assay was purchased 
from Promega corporation (Madison, WI, USA).  
RNeasy Mini Kit for RNA extraction and cDNA 
preparation kit were purchased from Qiagen, USA. The 
antibodies against PCNA, p21, p27, CDK4 and cyclin D 
were purchased from Abcam, USA, Cell Signalling 
Technologies, USA and Sigma (St. Louis, MO, USA). 
The anti-Rb secondary with HRP conjugate was also 
purchased from Sigma. The Caspase 3 Colorimetric 
Assay Kit was purchased from Sigma-Aldrich Inc. (St. 
Louis, MO, USA). 
Drug preparation for treatment 
Sitagliptin were dissolved in dimethylsulfoxide (DMSO; 
SIGMA, St. Louis, USA) to prepare a primary stock 
solution of 25 mM and stored at -20˚C. The final 
concentrations for treatments (i.e., 10 μM, and 100 μM) 
were subsequently prepared by diluting the primary 
stock with respective media for different cell lines. The 
concentration of DMSO used in this study did not affect 
cell survival and protein phosphorylation. Metformin is 
completely water soluble and was prepared using ultra-
purified DNase, RNase, mutagen free water as stock 
solution and then subsequent relevant concentrations 
required for the tests. 
Alamar Blue assay 
The inhibition of proliferation was assessed using 
Alamar Blue assay (THE CELL TITER-BLUE™ CELL 
VIABILITY ASSAY; Promega Corporation, Madison, 
USA). Cancer cell suspension was seeded to the wells of 
96-well microtiter plates and treated with different 
concentrations of drugs. The plates were then incubated 
at standard cell culture conditions.  20μL of Celltiter-
Blue™ reagent per 100 μL of cell culture medium is 
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then added in each well and incubated for another 3 h. 
The organic substance Resazurin undergoes a blue shift 
to form Resorufin. Later, the colorimetric analysis was 
completed as per manufacturer’s protocol and 
absorbance data were collected at 570 nm with a 
reference wave length of 600 nm, which reveals the 
inhibitory potential of the drugs. 
Cytotoxicity test with normal human peripheral 
blood mononuclear cell (PBMNC) 
Cytotoxicity test with normal human peripheral blood 
mononuclear cells (PBMC) was also performed. After 
informed consent, 5 mL of blood drawn from one of the 
authors was heparinized (10 U mL
-1
) and mixed with an 
equivalent quantity of normal saline. The homogeneous 
blood was coated on 3 mL of histopaque and centrifuged 
for 15-20 min at 1500 rpm at RT. PBMC were collected 
from the interface between histopaque and plasma, 
washed twice with normal saline and re-suspended in the 
culture medium. The cells were then maintained in 
standard culture conditions, in the presence or absence 
of the anti-diabetic drugs for 24 hrs. PBMC were 
stimulated with 2.5 mg mL
-1
 of phytohemoagglutinin 




Western blot analysis 
Cells were seeded for treatment onto 60 mm TC-treated 
plates (Nulgene, USA), washed with PBS at termination 
of treatment and lysed with RIPA lysis buffer (Sigma-
Aldrich, USA) containing protease inhibitor cocktail 
(Sigma-Aldrich, USA). The whole cell lysate samples 
were then centrifuged at 10000 rpm for 30 minutes at 
4˚C to collect the supernatant. Protein concentration is 
measured using Bradford reagent (Sigma-Aldrich, 
USA), and diluted 1:1 with SDS sample buffer (4% 
SDS, 20% glycerol, 0.5 M Tris-HCl (pH 6.8), 0.002% 
bromophenol blue). 50 μg of total protein, solubilised in 
SDS-sample buffer were resolved in each case in 
polyacrylamide (PAGE)-SDS gel system and electro-
transblotted onto a PVDF membrane and blocked with 
5% reconstituted non-fat dried milk (Sagar Skimmed 
Milk Powder, Amul, India). Membranes were incubated 
and probed with the following antibodies: rabbit-anti-
PCNA (abcam, UK), rabbit-anti-p53, rabbit-anti-p21, 
rabbit-anti-p27,  rabbit-anti-actin (all Cell Signaling 
Technologies, Leiden, The Netherlands) in a 1:1000 
dilution or anti-cyclinD1 (Santa Cruz Biotechnology, 
UK). Primary antibodies were stained using HRP-
coupled goat anti-rabbit or rabbit anti-mouse IgG and 
developed with ECL reagent (GE Healthcare Life 
Sciences, USA). Images were captured with the 
ImageQuant LAS 500 imaging system (GE Healthcare 
Life Sciences, USA). 
Flow-cytometric analysis of apoptosis 
The cells (1106) were treated with metformin, 
pioglitazone and sitagliptin for 72 hrs. The cells were 
then washed with phosphate buffer saline and 
centrifuged at 1300 rpm at 4˚C. The assay was then 
continued as per FITC Annexin V Apoptosis Detection 
Kit I (BD Pharmingen™; Material No. 556547) 
protocol. The cells were analyzed within 3-4 h by BD 
FACSVerse™ flow cytometer (BD Biosciences, USA) 
with BD FACSuiteTM software. Flow cytometer was set 
for collecting data of 10,000 cells in each group. Flow-
cytometric reading will be taken using 488 nm excitation 
and band pass filters of 530/30 nm (for FITC detection) 




MCF7 and HepG2 cells were analysed for apoptogenic 
activity by Hoechst [Hoechst 33342; Invitrogen, USA] 
staining following standard protocol
11
. The cells, treated 
or untreated, were added to a 24 well plate so that there 
remains a cell number of 1104. After 72 h of treatment 
the cells were washed with PBS and Hoechst 33342, 
diluted in PBS, was added to the wells of culture plate. 
After 15–20 minutes of incubation the cells were washed 
again with PBS and adequate culture medium was added 
to cover the surface of the wells of the culture plate. The 
cells were then observed and photograph was taken 
using EVOS® FL Cell Imaging System (Life 
Technologies, USA). 
Caspase 3 analysis using assay kit 
1107 number of Cancer cells were collected after drug 
treatment along with same number of normal untreated 
cells. Cell lysates were prepared and using the lysates 
their caspase-3 activities were determined using Sigma 
Caspase 3 Assay Kit (Sigma-Aldrich, USA) using 96 
Well Plate Microassay Method. Drug-treated and 
untreated cells were lysed according to the 
manufacturer’s protocol and the lysate including the kit 
chemicals were incubated and the absorbance was read 
at 405 nm wavelength using iMark™ Microplate 
Absorbance Reader (Biorad, CA, USA). 
Statistical Analysis 
Data were analysed by Student’s t-test or ANOVA 
wherever required. Experiments were conducted thrice 
and each test was performed in multiple well/numbers. 
Data has been represented as mean±SD wherever 
applicable and p < 0.05 was considered significant. 
RESULTS 
Determination of IC50 of the drugs in cancer cell 
lines and cytotoxicity test with normal human 
peripheral blood mononuclear cell (PBMNC) after 24 
hours of treatment 
The IC50 of the anti-diabetic drugs were determined on 
the basis of 24 hours treatment by applying alamar blue 
assay (THE CELL TITER-BLUE™ CELL VIABILITY 
ASSAY; Promega Corporation, Madison, USA). Table 1 
is showing the determined IC50 values for the anti-
diabetic drugs. 
Table 1: Determination of the IC50 of Metformin 
and Sitagliptin in MCF7 and HepG2 cells 
 IC50 in MCF7 IC50 in HepG2 
Metformin 15.03 mM 21.18 mM 
Sitagliptin 1.65 μM 2.2 μM 
Expressed as mean value 
After 24 h of treatment with each of the two drugs, the 
data stating the percentage of inhibition by the drugs 
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shows that the drugs had affected the proliferative 
cancer cells much more than they inhibited the 
PBMNCs. Figure 1 describes the results thoroughly. The 
selective cytotoxicity of the anti-diabetic drugs to spare 
the normal cells suggests the usefulness of the drugs in 
exploiting their anti-cancerous properties in diabetic 
patients with breast and liver cancers. 
 
 
Figure 1: After 24 h of treatment with both the drugs, the data explains the percentage of inhibition by the drugs which show 
that the drugs had affected the proliferative cancer cells much more than they inhibited the PBMNCs. A and B showing the 
comparison of cytotoxicity of metformin to MCF7 and HepG2 respectively in comparison with PBMCs whereas, C and D 
shows the effect of sitagliptin. 
 
Cytotoxicity studies revealed metformin to be more 
effective as compared to sitagliptin 
According to our analysis, all the drugs have more or 
less cytotoxic or cell growth inhibitory properties in 
MCF7 breast cancer cells and HepG2 hepatocellular 
carcinoma cells. The cytotoxicity data obtained has been 
expressed through the cell viability curve in figure 2A 
and 2B. Figure 2A explains the growth inhibitory 
properties of the anti-diabetic drugs on MCF7 breast 
cancer cells. From the apparent tendency of the curve it 
is clear, that the drugs pioglitazone and metformin have 
better effective cytotoxicity as compared with that of 
sitagliptin. The apparent tendency of cytotoxicity curve 
is almost similar in case of the other cell line we tested, 
the HepG2 (Figure 2B). But it seems the drugs are more 
efficient inhibitors of MCF7 cells. 
Analytical information, obtained from the detailed data, 
suggests that in case of both the cell lines, significant 
decrease in the viability of the cancer cells was observed 
only after 48 hours of treatment. After 48 hours, the 
cytotoxicity by sitagliptin was similar to that of by the 
other two drugs, especially in HepG2 cell line. But it 
was not the same by its measure in following treatment 
hours, 72 hours and 96 hours. After 96 hours, where the 
viability after treatment with sitagliptin 10 μM and 100 
μM are 88.29% and 79.89% it deepens to 62.37% with 
1mM metformin. In case of MCF7 cell line the 
cytotoxicity of sitagliptin is slightly enhanced; 87.82% 
and 78.92% with sitagliptin 10 μM and 100 μM 
respectively. The cell viability by metformin treatment 
has drastically fallen to 40.13% by metformin 1mM. 
Figure 2C and figure 2D shows the growth of MCF7 and 
HepG2 cells respectively, in culture dishes under the 
phase contrast microscope. 
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Figure 2: After determining the 24 hours’ IC50 of the 
two drugs, the MCF7 and HepG2 cells were subjected to 
cell viability study on a time dependent manner. Alamar 
blue assay data were collected after 6, 12, 24, 48, 72 and 
96 hours. Panel 2A (MCF7) and 2B (HepG2) clearly 
demonstrates the comparative effects of the two anti-
diabetic drugs in a time dependent manner. Panel 2C 
(MCF7) and 2D (HepG2) shows the phase contrast image 
of cell proliferation status after treating with drugs for 72 
hours. For 2A and 2B values were taken as mean±SD (* = 
p<0.05, ** = p<0.01 and *** = p<0.001). 
 
Fluorescent staining of cancer cell nucleus showed 
the cytotoxic efficacy of anti-diabetic drugs on 
cancer cells 
The cytotoxicity of the anti-diabetic drugs on cancer 
cell lines was re-confirmed via fluorescent staining. 
The live cell nuclei were stained using Hoechst 33342 
nuclear stain and the fluorescent image thus captured 
explained the previous data of decreasing cell viability 
by treating with anti-diabetic drugs. The data was 
collected after treating the cells for 72 h with or 
without drugs. 
Figure 3.1 demonstrates the effects of the anti-diabetic 
drugs upon MCF7 breast cancer cells very clearly. 
Panel A denotes the control population of MCF7 cell, 
where the number of nuclei as well as the number of 
healthy nuclei is fairly high. Compared with that, panel 
B showed very minimal cell killing activity and 
resulted in a pool of a good number of healthy cells, 
whereas, panel C depicted a very small number of 
healthy nuclei and most of them showed disintegrated, 
broken-down and condensed chromatin resulting in 
fragmented nucleus. These are all signs that indicate 
the induction of cell death. Here, panel B and C 
demonstrated the treatment with metformin 100 μM 
and 1 mM respectively. Treatment with sitagliptin had 
its impact but the lower dose of it, i.e., 10 μM, could 
hardly change the anatomy of the cells or rather their 
nuclei (panel D) as compared with control cells. 
However, the 100 μM treatment (panel E) showed 
some irregular chromatin staining that certainly 
suggests that sitagliptin 100 μM dose has potential 
cytotoxic effects that induced cell death. Although, the 
affectivity is much lower than that of metformin 1 mM 
dosage in MCF7 cells. 
Figure 3.2 demonstrates the effects of the anti-diabetic 
drugs upon HepG2 hepatocellular carcinoma cells. 
Fluorescent staining of HepG2 cell line demonstrated a 
similar kind of story. Panel A denotes control-
untreated HepG2 cells. Panel B and C shows the data 
of metformin 100 μM and 1 mM respectively. Panel D 
and E give away the result of sitagliptin treatment with 
10 μM and 100 μM doses. Similar to the results 
obtained in case of MCF7 cells, in this case also 
treatment with metformin 1 mM showed significant 
efficacy in inducing cell death (panel C) as compared 
with the 100 μM dose (panel B). Unlike in the case of 
MCF7 cells, in HepG2 cells sitagliptin showed a very 
little growth inhibitory signs and effect to cause 
cytotoxicity in case of 10 μM dose of the drug (panel 
D). However, the 100 μM dose (panel E) had been 
observed to induce cell death to some extent.
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Figure 3: Fluorescent microscopic analysis after staining with Hoechst 33342 nuclear stain reveals the status of the nuclear 
fragmentation due to the treatment with sitagliptin and metformin. In this figure, metformin has been observed to be the more 
potent anti-cancer agent compared to sitagliptin especially in HepG2 cells (Figure 3.2). Nevertheless, sitagliptin also could 
induce the chromosomal disintegration and nuclear fragmentation as pointed by white arrow heads in the figure especially in 
MCF7 cells (Figure 3.1). [A=Control, B=Metformin 100 M, C=Metformin 1 mM, D=Sitagliptin 10 M, and E=Sitagliptin 
100 M.] 
AnnexinV-FITC/PI binding study explains the 
apoptogenic potentiality against cancer cells by the 
anti-diabetic drugs 
In case of both drugs, two doses, including the one 
similar to the clinical dose, had been used to investigate 
the pro-apoptogenic potential of the anti-diabetic drugs. 
After 72 hours of treatment, metformin 1mM and 
pioglitazone 10 & 50 μM significantly reduced the 
number of normal cells and increased with the similar 
proportion the early and late apoptotic cells. Table-2 and 
table-3 shows the effect of metformin, sitagliptin and 
pioglitazone on MCF-7 and HepG2 cells. 
 
Table 2: Effect of metformin and sitagliptin on flow cytometric AnnexinV-FITC/PI binding assay for MCF7 cell line 
at 72 hours 
 Normal Cells Early Apoptotic Cells Late Apoptotic Cells Necrotic Cells 
Control 74.94±2.92 8.87±1.84 14.78±2.29 1.42±0.67 
Met 100 μM 61.53±0.86 8.09±0.62 27.72±1.45*** 2.66±0.91 
Met 1 mM 34.01±0.75 34.79±0.19*** 28.96±0.71*** 2.24±1.51 
Sita 10 μM 62.28±1.33 8.00±0.82 25.99±0.63*** 3.73±1.05 
Sita 100 μM 61.8±0.63 7.56±0.66 27.18±1.63*** 3.46±1.54 
Data were represented as mean±SD.                    *** p< 0.001 (control vs. treatment).                     ** p<0.01 (control vs. treatment) 
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Table 3: Effect of metformin and sitagliptin and on flow cytometric AnnexinV-FITC/PI binding assay for HepG2 cell 
line at 72 hours 
 Normal Cells Early Apoptotic Cells Late Apoptotic Cells Necrotic Cells 
Control 99.83±0.09 0.09±0.02 0.02±0.02 0.06±0.08 
Met 100 μM 96.5±0.40 2.97±0.08*** 0.14±0.11*** 0.40±0.29 
Met 1 mM 94.23±0.32 5.28±0.44*** 0.35±0.05*** 0.15±0.11 
Sita 10 μM 96.87±0.19 2.6±0.13*** 0.32±0.07*** 0.21±0.13 
Sita 100 μM 96.35±0.49 2.52±0.37*** 0.40±0.23*** 0.73±0.21 
Data were represented as mean±SD.                 *** p< 0.001 (control vs. treatment) 
In MCF7 cells (Table-2, Figure 4.1), after 72 hours of 
treatment, untreated normal cell pool was 74.94%±2.92 
which significantly reduced to 61.53%±0.86 
approximately when treated with 100 μM metformin. 
The normal cell pool further got deducted to 
34.01%±0.75 in the treatment group, treated with 
metformin 1 mM. In comparison, sitagliptin, though 
affected the normalcy of cells significantly, reduced the 
population of normal cells only up to 61.80%±0.63 with 
100 μM dose. As a result, there was a sharp increase in 
the total apoptotic cells’ population, although, 
specifically, early apoptotic population could not be 
observed which may be due to early shifting of 
apoptotic phases of MCF7 cells in the experiments. 
 
 
Figure 4: AnnexinV-FITC/PI binding assay by flow cytometer showed significant apoptogenic potential of sitagliptin and 
metformin. In case of MCF7 cells (Figure 4.1) sitagliptin could only increase the late apoptotic population significantly, but 
in HepG2 cells (Figure 4.2) sitagliptin induced both early and late apoptotic mechanisms. Table 2 and table 3 showed 
statistical data expressed as mean±SD (*** = p<0.001) 
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In HepG2 cells (Table-3, Figure 4.2), nearly similar 
scenario was observed with treated and untreated 
population. After 72 hours, the data was collected by flow 
cytometric analysis. Compared to the untreated control 
cells, the metformin 100 μM and 1 mM reduced cell pool in 
normal cell population and increased in early apoptotic cell 
populations significantly to 2.97%±0.08 and 5.28%±0.44 
from 0.09%±0.02 in the untreated control group. Sitagliptin 
also induced apoptosis but not in a dose dependent manner 
as in the case of metformin, and increased the early 
apoptotic cell population to 2.6±0.13 and 2.52±0.37 by 10 
μM and 100 μM doses respectively. Eventually the similar 
sort of significant increase in the population of late 
apoptotic population was observed with all similar 
treatment groups. 
Protein expression data explains the anti-proliferative 
role of the drugs 
To investigate regarding the molecular mechanisms behind 
the anti-cancer potentials of the anti-diabetic drugs of our 
concern in this particular study, we targeted a few growth-
regulating molecules. We choose to study some basic 
protein expressions that could justify the role of the drugs 
in this context.  
PCNA: The expression pattern of proliferating cell nuclear 
antigen (PCNA) -protein clearly suggests the drugs’ anti-
proliferative role in cancer cells, especially metformin and 
pioglitazone. From figure 3 the difference of anti-
proliferative efficacy between the drugs can be understood 
clearly. Panel A demonstrates that in MCF7 cells, DNA 
replication was significantly reduced after 72 hours of 
treatment with metformin 1 mM. Compared with 
metformin, sitagliptin treatment reduced the expression of 
PCNA but only to a much lesser extent. Panel A', derived 
from immune blot of panel A showed the densitometric 
analysis of the protein expression. 
Similar expression pattern was obtained from panel B 
which demonstrates the PCNA expression in HepG2 cell 
line. Sitagliptin 100 μM treatment for 72 hours did reduce 
protein expression significantly as compared with untreated 
cells. Same as the MCF7 cell line, metformin 1 mM 
treatment also, significantly reduced the expression of 
PCNA. Panel B' designates the densitometric analysis of 
panel B. 
Cell cycle regulatory protein: Cell cycle regulatory 
proteins’ expression were investigated and compared for 







 and CDK-4 were among the common proteins which 
were tested in both the cell lines (Figure 5). 
Figure 5.1 Panels A', B', B'', C', C'', D', and E' describe the 
densitometric expression analysis of the cell cycle 
regulating proteins in MCF7 breast cancer cell line. It was 
evident from the immuno blot’s densitometric data that 
p21
Cip1/Waf1
 protein expression was significantly increased 





 were observed to be significantly 
higher when treated with metformin as compared with 
untreated cells or sitagliptin treated cells as well. But 
treatment with sitagliptin certainly showed an anti-
cancerous impact. CDK-4 and cyclin D protein expressions 
were also reduced significantly by metformin 1mM and 
sitagliptin 100 μM in comparison with untreated cells.  
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Figure 5: Western blotting analysis of proteins from the whole cell lysate after 72 hours of treatment, demonstrated the 
significant role of metformin and sitagliptin in inhibiting the cell growth in MCF7 breast cancer cells in vitro (Figure 5.1). 
Panel A shows the comparative activity of the drugs (sitagliptin, metformin and pioglitazone) in inhibiting the expression of 
PCNA of which densitometric analysis has been shown in panel A´. Likewise panels B, C and D shows comparative activity 
of drugs upon the expressions of CIP/KIP inhibitors (p21 and p27), CDK4 and Cyclin D1. Figure 5.2 demonstrated that 
sitagliptin could actually reduce the expression of PCNA significantly but it did not show significant impact upon the 
expression of p21/p27 or CDK-4 whereas metformin 1mM was significant in its activity to decrease the cell proliferative 
protein expressions in both MCF7 and HepG2 cells. Densitometric diagrams were prepared with mean±SD of densitometric 
data of the protein blots, repeated thrice. (* = p<0.05, ** = p<0.01 and *** = p<0.001). 
 
Figure 5.2 shows the same protein expression in HepG2 
cells. Expression pattern as obtained from HepG2 cells 
goes in line with that of MCF7 cells except that 
sitagliptin showed no significant impact in regulating 
the cell cycle proteins to show anti-cancer character. 
The cells treated with metformin showed significant 





clearly understood from the densitometric analysis. The 
expression of CDK-4 significantly reduced after treating 
with metformin in contrast with sitagliptin. Panels A' 
and B' demonstrates the densitometric analysis of the 
blot. 
Caspase-3 study resolves the apoptogenic potential of 
the drugs 
To know if the drugs enhance the apoptotic mechanisms 
of the cancer cell lines (MCF7 and HepG2) the caspase-
3 expression study was performed using Sigma Caspase 
3 Assay Kit (Sigma-Aldrich, USA). Figure 6 
demonstrates the outcome of the assay. 
Panel A clearly states that when MCF7 cells were 
treated with sitagliptin (100 μM) and metformin (1 
mM), the cells were potentially induced to activate their 
caspase-3 activity. From the Panel B, it was clear that 
sitagliptin and metformin also enhanced caspase-3 
activity in HepG2 cells. 
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Figure 6: Caspase-3 activity study demonstrated that metformin and sitagliptin had significant impact upon the induction of 
caspase-3 to increase apoptogenic machinery in both the cell lines (A=MCF7, B=HepG2). The experiment was repeated four 
times and the values are given as mean±SD. (* = p<0.05 and *** = p<0.001). 
DISCUSSION                                                                                                  
In current era, established drugs and other 
pharmacological substances, known to be useful against 
diseases, are being unveiled to use their unknown 
therapeutic potentials in various other 
pathophysiological conditions. Complexity and 
intracellular signalling meshwork and exclusive 
responsive behaviour of the pharmacological agents in 
any specific tissue are opening up newer uses other than 
their current use. In line with the same conception, 
herein, we are assessing the anti-cancer potencies of a 
useful type-2 anti-diabetic drug sitagliptin in comparison 
with another drug, metformin, a biguanide. Since 
investigators from different parts of the globe have 
demonstrated through pre-clinical in vivo and in vitro 
studies about increased pro-cancerous changes with the 
use of insulin or insulin secretagogues (sulfonylurea), 
the other anti-diabetics required a reconsideration 
regarding their use against cancer. In line with this, in 
our previous investigation it was shown that pioglitazone 
can reduce MCF7 cancer growth through sustained 
activation of MAPK in a PPARγ independent pathway. 
It has been put forward for the first time before the 
scientific community that in MCF7 cells pioglitazone 




Several scientific interpretations have indicated about 
the hostile effects of using agonists of GLP-1 pathway
12, 
13, 14
. The hazard of pancreatic cancer and pancreatitis is 
reported to be higher in individuals with diabetes and 
obesity than in the healthy people. The fact has been 
found that GLP-1 receptor (GLP‑1R) activation inspires 
calcitonin secretion and countersigns the expansion of 
C‑cell hyperplasia and medullary thyroid cancer (MTC) 
in rodents. Cases of depression have also been reported. 
Sitagliptin sometimes increases creatinine levels 
15
. 
Pharmacological data suggest there might be an 
increased risk of cancer and muscular and neurological 
disorders. In contrast, we found out that sitagliptin, an 
agonist of GLP-1, could induce the p21 and p27 
expression up to a certain extent in MCF7 cell line. This 
shows the sign of anti-cancer potentials of sitagliptin. 
Anti-proliferative character of the drug was also 
supported by the fact that treatment with the same could 
significantly decrease the expression of PCNA 
(proliferating cell nuclear antigen) in both cell lines. As 
stated earlier, sitagliptin had no supporting anti-cancer 
properties, rather it induced inflammation in certain 
tissues 
16
 but our present data was in line with our recent 
review which illustrated various beneficial effects of the 
drug as well 
17
. 
Sliwinska A et al. (2015) in their report 
18
 suggested that 
sitagliptin had no efficacy in inducing cell death in 
HepG2 cells. Abo-Haded HM et al. (2017) recently 
reported 
19
 sitagliptin had a hepatoprotective effect 
against methotrexate induced liver toxicity. Wang et al. 
(2015) also explained in certain ischemic environment, 
sitagliptin inducing anti-apoptotic signaling. 
20
. Tseng 
CH in 2017 stated that Sitagliptin may reduce prostate 
cancer risk in male patients with type 2 diabetes 
21
. 
Tseng CH in 2017 stated that Sitagliptin may be able to 
reduce breast cancer risk in Women with type 2 diabetes 
22
 but no evidence has been suggested regarding its 
efficacy in modulating the in vitro cell signaling thereby 
stopping cell proliferation. Whereas, we have found out 
an apoptogenic behaviour in sitagliptin when treated 
against MCF7 breast cancer cell lines and HepG2 liver 
cancer cell line. These observations have been reported 
for the first time in similar circumstances. In our study 
we demonstrated that though a lower than that of 
metformin but certain impact of sitagliptin on early 
apoptogenic efficacy in HepG2 and late apoptogenic 
efficacy on MCF7 as well as the caspase-3 activity 
expression in both cell lines. 
DPP4 promoted EGF-induced epithelial cell 
transformation and mammary tumorigenesis via 
induction of PIN1 expression, suggesting that sitagliptin 
targeting of DPP4 could be a treatment strategy in 
patients with breast cancer 
23
. In line with the previous 
finding, we showed for the first time that, Sitagliptin 
could induce an anti-cancer mechanism that in turn 
could significantly induce p21 and p27 expression in 
MCF7 breast cancer cell and suppressed PCNA 
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expression although it showed insignificant changes of 
p21, p27 and CDK4 expression while considering 
HepG2 cells. 
AnnexinV-FITC/PI binding assay by flow cytometer 
demonstrated that only metformin but not sitagliptin 
could induce early apoptotic cell death in breast cancer 
cells but it could vastly induce the late apoptotic signs in 
MCF7 cells whereas in liver cancer cell lines sitagliptin, 
like metformin and pioglitazone, was observed to induce 
cell death, both early and late apoptosis, significantly. 
Metformin and Sitagliptin induced Capase3 activity dose 
dependently though sitagliptin did show a significantly 
lower effect than the other drugs. But to summarize the 
experiments, it should be emphasized that sitagliptin, 
unlike previous reports from various investigators 
2, 18-22
, 
has been observed to show cell-death inducing 
characters. 
In conclusion, we found sitagliptin to show a potential 
cytotoxic effect on both type of cancer cells (MCF7 and 
HepG2). It has also showed certain impact on early 
apoptogenic efficacy in HepG2 and late apoptogenic 
efficacy on MCF7 as well as the caspase-3 activity 
expression in both cell lines. In the line of our study it 
might be concluded that sitagliptin has a potent anti-
cancerous activity, though it was observed to be lesser 
than that of metformin, though further investigation is 
needed to establish its potentiality as a useful drug for 
the diabetic cancer condition patients.  
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